世界中医药

目的：探讨黄葵胶囊治疗临床期糖尿病肾病的临床疗效，及其对某些炎性反应因子的影响，并对其部分机制进行探讨。方法：选择本院内分泌科2012年2月至2014年2月收治的120例确诊为临床期糖尿病肾病的患者为研究对象，采用随机数字表随机分为2组，每组60例。对照组给予西医常规的治疗方案。观察组在对照组的基础上加用黄葵胶囊口服治疗，5粒，3次/d，2组均治疗8周。同时监测2组患者治疗前及治疗后血糖、血脂、血压、肾功能及hs-CRP、TNF-α、IL-6、IL-8等炎性反应因子的变化。结果：经治疗后，观察组的有效率明显优于对照组，差异具有统计学意义（P<0.05）；2组的血糖、血脂、血压均得到控制，差异较治疗前均具有统计学意义（P<0.05）；观察组血糖的控制情况上优于对照组，差异具有统计学意义（P<0.05）；2组血压、血脂的控制情况比较上，差异无统计学意义（P>0.05）；2组的尿素氮、24 h尿蛋白、血肌酐均得到改善，差异均具有统计学意义（P<0.05）；观察组尿素氮、24 h尿蛋白、血肌酐明显优于对照组，差异均具有统计学意义（P<0.05）；2组患者血清中治疗后hs-CRP、TNF-α、IL-6、IL-8的含量均有所下降，差异均具有统计学意义（P<0.05）；而观察组的下降程度较对照组更为明显，差异均具有统计学意义（P<0.05）。结论：黄葵胶囊可改善患者的肾功能，降低糖尿病肾病患者hs-CRP、TNF-α、IL-6、IL-8，临床疗效显著，值得临床推广应用。

English Summary:

To investigate the therapeutic effect of Huangkui Capsule for diabetic nephropathy at clinical stage and its impact on certain inflammatory factors, and to discuss its mechanism.Methods:A hundred and twenty patients who were admitted in the endocrinology department of our hospital from February 2012 to February 2014 and diagnosed as diabetic nephropathy at clinical stage were included as the research subjects and randomly divided into two groups with 60 cases in each. Patients in the control group received conventional western medicine treatment and five Huangkui capsules with three times a day were added for patients in the observation group compared with the control group. Patients in both groups were treated for 8 weeks. Changes of blood sugar, blood lipids, blood pressure, renal function and hs-CRP, TNF-α, IL-6, IL-8 and other inflammatory factors of patients in two groups were carefully monitored before and after treatment.Results:After treatment, the efficiency of the observation group was obviously superior to that of the control group, which showed statistically significant difference (P<0.05); blood sugar, blood lipids and blood pressure of the two groups were controlled with statistically significant differences (P<0.05 ); blood glucose of the observation group was better controlled than that of the control group, showing statistically significant difference (P<0.05); there was no statistically significant difference in control of blood pressure and blood lipids for the two groups (P>0.05). Urea nitrogen, 24 h urine protein and serum creatinine of the two groups were improved with statistically significant differences (P<0.05); those of the observation group were significantly better than those of the control group, showing statistically significant differences (P<0.05). Serum hs-CRP, TNF-α, IL-6, and IL-8 levels after treatment of both the two groups declined, which showed statistically significant differences (P<0.05); and the decrease in the observation group was significant than that of the control group, with statistically significant differences (P<0.05).Conclusion:Huangkui capsule may improve renal function for patients with diabetic nephropathy and reduce hs-CRP, TNF-α, IL-6, and IL-8 level with significant clinical effects, which is worthy of clinical application.

查看全文查看/发表评论下载PDF阅读器